Certain Blood Separation and Cell Preparation Devices; Institution of Investigation, 8891-8892 [2019-04475]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 48 / Tuesday, March 12, 2019 / Notices
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
By order of the Commission.
Issued: March 7, 2019.
William Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2019–04474 Filed 3–11–19; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1099]
Certain Graphics Processors and
Products Containing the Same; Notice
of Commission Determination Not To
Review an Initial Determination
Terminating the Investigation in Its
Entirety Based on Settlement;
Termination of the Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 49) terminating the
investigation in its entirety based on
settlement. The investigation is
terminated.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Robert Needham, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–5468. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on February 5, 2018, based on a
complaint filed by ZiiLabs Inc., Ltd. of
Hamilton, Bermuda (‘‘ZiiLabs’’). 83 FR
VerDate Sep<11>2014
16:50 Mar 11, 2019
Jkt 247001
5141–42. The complaint alleges
violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain graphics
processors and products containing the
same that infringe certain claims of U.S.
Patent Nos. 6,181,355; 6,900,800;
8,144,156; and 8,643,659. Id. at 5141.
The Commission’s notice of
investigation named as respondents
ASUSTeK Computer Inc. of Taipei,
Taiwan; ASUS Computer International
of Freemont, California; EVGA
Corporation of Brea, California; Gigabyte
Technology Co., Ltd. of New Taipei
City, Taiwan; G.B.T. Inc. of City of
Industry, California; Micro-Star
International Co., Ltd. of New Taipei
City, Taiwan; MSI Computer Corp. of
City of Industry, California; Nintendo
Co., Ltd. of Kyoto, Japan; Nintendo of
America, Inc. of Redmond, Washington;
Nvidia Corporation of Santa Clara,
California (‘‘Nvidia’’); PNY
Technologies Inc. of Parsippany, New
Jersey; Zotac International (MCO) Ltd. of
Macau, China; and Zotac USA Inc. of
Duarte, California. Id. at 5142. The
Office of Unfair Import Investigations is
not participating in this investigation.
Id.
On February 8, 2019, ZiiLabs filed an
unopposed motion to terminate the
investigation in its entirety based on
several settlement agreements among
ZiiLabs, Nvidia, and non-party RPX
Corporation. The motion indicated that
the agreements included a release for all
respondents in the investigation.
On February 12, 2019, the presiding
administrative law judge issued the
subject ID, granting the motion and
terminating the investigation. No party
petitioned for review of the ID.
The Commission has determined not
to review the subject ID. The
investigation is terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: March 6, 2019.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2019–04405 Filed 3–11–19; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
8891
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–1147]
Certain Blood Separation and Cell
Preparation Devices; Institution of
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 30, 2019, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of RegenLab USA LLC of New
York, New York. An amended
complaint was filed on February 15,
2019. The amended complaint alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain blood separation and cell
preparation devices by reason of
infringement of certain claims of U.S.
Patent No. 10,064,894 (‘‘the ’894
patent’’). The amended complaint
further alleges that an industry in the
United States exists or in the process of
being established as required by the
applicable Federal Statute.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and a cease and
desist order.
ADDRESSES: The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW, Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT: The
Office of Unfair Import Investigations,
U.S. International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
SUMMARY:
E:\FR\FM\12MRN1.SGM
12MRN1
8892
Federal Register / Vol. 84, No. 48 / Tuesday, March 12, 2019 / Notices
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2017).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
March 6, 2019, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
1–24 of the ’894 patent, and whether an
industry in the United States exists or
in the process of being established as
required by subsection (a)(2) of section
337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘blood separation and
cell preparation devices that allow
clinicians to collect a patient’s blood
and separate platelet rich plasma from
the blood, which is then used to treat
the patient’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is:
RegenLab USA LLC, 575 Madison
Avenue, Suite 1006, New York, NY
10022.
(b) The respondent is the following
entity alleged to be in violation of
section 337, and is the party upon
which the complaint is to be served:
Estar Technologies, Ltd., 15 Hamerkava
Street, Holon 5885111, Israel.
Eclipse MedCorp, LLC, 5916 Stone
Creek Drive, Suite 120, The Colony,
TX 75056.
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
VerDate Sep<11>2014
16:50 Mar 11, 2019
Jkt 247001
submitted by the named respondent in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of the respondent to file a
timely response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: March 7, 2019.
William Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2019–04475 Filed 3–11–19; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–595–596 and
731–TA–1401, 1403, 1405–1406 (Final)]
Large Diameter Welded Pipe From
Canada, Greece, Korea, and Turkey;
Scheduling of the Final Phase of
Antidumping and Countervailing Duty
Investigations
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
DATES:
March 6 2019.
FOR FURTHER INFORMATION CONTACT:
Lawrence Jones (202) 205–3358), Office
of Investigations, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION: Effective
August 27, 2018, the Commission
established a general schedule for the
conduct of the final phase of its
investigations on large diameter welded
(LDW) pipe from Canada, China, Greece,
India, Korea, and Turkey,1 following
preliminary determinations by the U.S.
Department of Commerce (‘‘Commerce’’)
that certain benefits which constitute
subsidies within the meaning of section
703 of the Act (19 U.S.C. 1671b) are
being provided to manufacturers,
producers, or exporters in China, India,
Korea, and Turkey of large diameter
welded (LDW) pipe, and that such
products from Canada, China, Greece,
India, Korea, and Turkey are being sold
in the United States at less than fair
value (LTFV) within the meaning of
section 733 of the Act (19 U.S.C.
1673b).2 Notice of the scheduling of the
final phase of the Commission’s
investigations and of a public hearing
held in connection therewith was given
by posting copies of the notice in the
Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register on
September 6, 2018 (83 FR 45279). The
hearing was held in Washington, DC, on
November 6, 2018, and all persons who
requested the opportunity were
permitted to appear in person or by
counsel. Following affirmative final
determinations by Commerce regarding
LTFV and subsidized imports of LDW
pipe from China and India, the
Commission issued its final
determinations that an industry in the
United States was materially injured by
reason of LTFV and subsidized imports
of LDW line pipe from India; that an
industry in the United States is
materially injured by reason of LTFV
and subsidized imports of LDW
structural pipe from China; and that an
industry in the United States is
threatened with material injury by
reason of LTFV imports of LDW line
pipe from China. Further, the
Commission has terminated the
countervailing duty investigation on
1 Large Diameter Welded Pipe From Canada,
China, Greece, India, Korea, and Turkey;
Scheduling of the Final Phase of Countervailing
Duty and Antidumping Duty Investigations, 83 FR
45279, September 6, 2018.
2 See generally 83 FR 30690–30699, June 29,
2018, and 83 FR 43640–43656, August 27, 2018.
E:\FR\FM\12MRN1.SGM
12MRN1
]]>Agencies
[Federal Register Volume 84, Number 48 (Tuesday, March 12, 2019)]
[Notices]
[Pages 8891-8892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-04475]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Inv. No. 337-TA-1147]
Certain Blood Separation and Cell Preparation Devices;
Institution of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on January 30, 2019, under section
337 of the Tariff Act of 1930, as amended, on behalf of RegenLab USA
LLC of New York, New York. An amended complaint was filed on February
15, 2019. The amended complaint alleges violations of section 337 based
upon the importation into the United States, the sale for importation,
and the sale within the United States after importation of certain
blood separation and cell preparation devices by reason of infringement
of certain claims of U.S. Patent No. 10,064,894 (``the '894 patent'').
The amended complaint further alleges that an industry in the United
States exists or in the process of being established as required by the
applicable Federal Statute.
The complainant requests that the Commission institute an
investigation and, after the investigation, issue a limited exclusion
order and a cease and desist order.
ADDRESSES: The complaint, except for any confidential information
contained therein, is available for inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Room 112, Washington,
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are
advised that information on this matter can be obtained by contacting
the Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov. The
public record for this investigation may be viewed on the Commission's
electronic docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import
Investigations, U.S. International Trade Commission, telephone (202)
205-2560.
SUPPLEMENTARY INFORMATION:
[[Page 8892]]
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337 and in section 210.10 of the Commission's Rules of Practice
and Procedure, 19 CFR 210.10 (2017).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on March 6, 2019, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(B) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain products
identified in paragraph (2) by reason of infringement of one or more of
claims 1-24 of the '894 patent, and whether an industry in the United
States exists or in the process of being established as required by
subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``blood separation and
cell preparation devices that allow clinicians to collect a patient's
blood and separate platelet rich plasma from the blood, which is then
used to treat the patient'';
(3) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainant is:
RegenLab USA LLC, 575 Madison Avenue, Suite 1006, New York, NY 10022.
(b) The respondent is the following entity alleged to be in
violation of section 337, and is the party upon which the complaint is
to be served:
Estar Technologies, Ltd., 15 Hamerkava Street, Holon 5885111, Israel.
Eclipse MedCorp, LLC, 5916 Stone Creek Drive, Suite 120, The Colony, TX
75056.
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
(4) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondent in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be
considered by the Commission if received not later than 20 days after
the date of service by the Commission of the complaint and the notice
of investigation. Extensions of time for submitting responses to the
complaint and the notice of investigation will not be granted unless
good cause therefor is shown.
Failure of the respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: March 7, 2019.
William Bishop,
Supervisory Hearings and Information Officer.
[FR Doc. 2019-04475 Filed 3-11-19; 8:45 am]
BILLING CODE 7020-02-P
